DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20172911

The effects of combined therapy of myo-inositol and D-chiro inositol in reduction of the individual components of metabolic syndrome in overweight PCOS patients compared to myo-inositol supplementation alone: a prospective randomised controlled trial

Manideepa Pande, Ashish Seal, Sukanta Mishra, Arup Dasgupta, Mousumi Sengupta, Rinini Dastider

Abstract


Background: Polycystic ovarian syndrome (PCOS) is one of the most common endocrine disorder affecting five to ten percent women of reproductive age group. Variability of signs and symptoms along with metabolic syndrome as one of the long term complications make it worthy of early diagnosis and treatment. Medical management of PCOS is aimed at the treatment of metabolic derangements, anovulation, hirsutism, and menstrual irregularities.

Methods: 140 patients, using inclusion and exclusion criteria, were selected and randomly divided into two groups (seventy in each) and age, BMI, waist hip ratio, blood pressure (systolic, diastolic), serum fasting insulin, fasting blood sugar, total cholesterol, HDL, LDL, triglycerides were measured. Study group were given {Myo-inositol (550 mg) + D-chiro-inositol (13.8 mg)} (MI+DCI) twice daily and the control group were given Myo-inositol (1 gm) (MI) twice daily for six months. Same variables were measured at the end of three and six months and compared with repeated measurement ANOVA using SPSS (version 20).

Results: Comparison between these two groups before study was non-contributory. Combined drug therapy has provided statistically significant decrease in BMI, W:H ratio, Diastolic BP, Fasting blood sugar at the end of both 3rd and 6th month but in case of LDL it was at the end of 3 months. Combined drug therapy also increased the HDL level significantly in both the occasions.

Conclusions: Combined medical therapy by (MI+DCI) is very much helpful in reducing the metabolic complications of PCOS without any major side effects.


Keywords


Anovulation, D-chiro-inositol, Hirsutism, Myo-inositol, PCOS

Full Text:

PDF

References


Genazzani AD, Battaglia C, Malavasi B, Strucchi C, Tortolani F, Gamba O. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil Steril. 2004;81(1):114-9.

Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25.

Azziz RJ. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. Clin Endocrinol Metab. 2006;91(3):781-5.

Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006;91(11):4237-45.

5. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91(2):456-88.

Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.

Vause TD, Cheung AP, Sierra S, Claman P, Graham J, Guillemin JA et al. Ovulation induction in polycystic ovary syndrome. J Obstet Gynaecol Can. 2010;32(5):495-502.

Lisi F, Carfagna P, Oliva MM, Rago R, Lisi R, Poverini R et al. Pretreatment with myo-inositol in non-polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF: a pilot study. Reprod Biol Endocrinol. 2012;10:52.

Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R et al. Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline. J Clini Endocrinol Metab. 2013;98(12):2013-2350.

Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR) (Letter). Diabet Med. 1999;16:442-3.

Iuorno MJ, Jakubowicz DJ, Baillargeon JP, Dillon P, Gunn RD, Allan G et al. Effects of D-chiroinositol in lean women with the polycystic ovary syndrome. Endocr Pract. 2002;8:417-23.

Heimark D, McAllister J, Larner J. Decreased Myo-inositol to chiro-inositol(m/c) ratios and increased m/c epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls. Endocr J. 2014;61(2):111-7.

Unfer V, Carlomagno G, Papaleo E, Vailati S, Candiani M, Baillargeon JP. Hyperinsulinaemia alters myo-inositol to d-chiro-inositol ratio in the follicular fluid of PCOS patients. Reprod Sci. 2014;21(7):854-58.

Minozzi M, Nordio M, Pajalich R.. The combined therapy myo-inositol plus d-chiro-inositol, in a physiological ratio, reduces the cardio-vascular risk by improving the lipid profile in PCOS patients. Eur Rev Med Pharmacol Sci. 2013;17:537-40.

Nordio M, Proietti E. The Combined therapy myo-inositol and d-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol alone. Eur Rev Med Pharmacol Sci. 2012;16:575-81.